Chemoradiotherapy for Advanced Esophageal Cancer

ConditionEsophageal Cancer

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorAHS Cancer Control Alberta

About this trial

This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with unresectable esophageal cancer.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Biopsy proven carcinoma of the esophagus.

Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness.

Symptomatic patients with Mellow Dysphagia Scores of ≥ 1 i.e. able to eat only some solids.

ECOG Performance status ≤ 2.

Disqualifiers

Previous radiotherapy delivered to the chest.

Synchronous active malignancies.

Pregnant or lactating patients: women of child bearing potential must have a negative serum pregnancy test within 7 days of Treatment Visit 1. Women or men of child bearing potential must use effective contraception (defined by the use of two birth control methods, which can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy). Subjects must start using birth control from the time they have signed the Informed Consent Form prior to start of therapy until 120 days post completion of study therapy or study discontinuation, which must be documented in the eCRF.

Patients unfit for any treatment component, including absolute contraindications for radiotherapy or Connective Tissue Disease.

Trial design

Design model

Single group

Treatments tested in this trial

Carboplatin and Taxol (paclitaxel)
Drug
Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
External Beam Radiation
Radiation
Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.

Treatment groups

50 Participants

are divided into 1 treatment group

Group A: Chemotherapy with Concurrent RadiationExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

Proportion of patients who achieve relief of dysphagia

Will be measured as the proportion of patients who achieve relief of dysphagia, defined as improvement of at least one point on the Mellow Dysphagia Score, measured at Day 57 after the start of radiotherapy, and maintained for at least 28 calendar days (until the Day 85 visit).

Time frame

up to day 85

Secondary outcomes

Dysphagia progression free survival

Will be measured from screening to the time of first progression of dysphagia. Progression of dysphagia will be defined as follows: * A drop of at least 1 point on the 5 point Mellow Dysphagia Score, * Stricture requiring intervention, or * Death, Other secondary objectives as follows: Time to achieving any response in dysphagia after treatment as measured by an improvement of at least 1 point on the 5 point Mellow Dysphagia Score. Number of patients receiving secondary treatment (radiation, chemotherapy or stenting), Utility assessments pre to post treatment and at 3 and 6 months, Quality of life differences post treatment and at 3 and 6 months. Measures of biological/serological correlates of response, Acute and late toxicity.

Time frame

6 Months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

AHS Cancer Control Alberta

Lead sponsor

Source ClinicalTrials.gov

Apply now